Annals of Surgical Oncology

, Volume 25, Issue 12, pp 3709–3710 | Cite as

ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer—A Multicenter Study

  • Anna FagottiEmail author
ASO Author Reflections



There are no conflicts of interests.


  1. 1.
    Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017;35(Suppl; abstr 5501).CrossRefGoogle Scholar
  2. 2.
    Coleman R, Enserro D, Spirtos N, et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG Oncology/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36 (suppl; abstr 5501).CrossRefGoogle Scholar
  3. 3.
    Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011;22:1127–1132.CrossRefGoogle Scholar
  4. 4.
    Bookman MA, Tyczynski JE, Espirito JL,Wilson TW, Fernandes AW. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol. 2017;146:58–63.CrossRefGoogle Scholar
  5. 5.
    Marchetti C, De Leo R, Musella A, et al. BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study. Ann Surg Oncol. 2018. Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Fondazione Policlinico Universitario A. Gemellli, IRCCSUniversità Cattolica del Sacro CuoreRomeItaly

Personalised recommendations